Large revenue increase Merck & Co expected

Huge increase Merck KGaA & Co expected

Over the past book year the analyst estimate the revenue to be around 39,85 billion dollars. This is way more than the 2014's revenue of 14,28 billion dollars. The consensus of the analysts for 2015 is a net profit of 10,31 billion dollars.

For 2015 the consensus of the earnings per share of Merck KGaA & Co is at profit of 3,71 dollars. Based on this the price/earnings-ratio equals 14,85.

The consensus of the dividends per share is at 1,84 dollars. Consequently the dividend return is around 3,34 percent. On average the stocks in this sector yield a dividend return of around 0,65 percent.

The stock Merck KGaA & Co is covered by 6 analysts. The average target price for Merck KGaA & Co is at 75,29 dollars. This is 37 percent more than the current stock price of 55,08 dollars.

The stocks Evotec , Mithra and Kiadis in the sector The pharmaceutical sector have the most buy recommendations. The 3 most recent recommendations for the pharmaceutical sector were provided by BMO Capital Markets (hold, 62,00 dollars), Jefferies & Co. (hold, 51,00 dollars) and Credit Suisse (hold, 56,00 dollars).

Merck KGaA & Co's book value/price equals 0,33. The pharmaceutical sector now trades at a Shiller PE of 24.91. The stock now trades at 55,08 dollars. This equals 14 times the 2014's earnings per share.